Special Edition

Special Edition

On location

Pinpointing the Mechanisms that Transform MGUS into Myeloma

A molecular study of monoclonal gammopathy of undetermined significance (MGUS) and myeloma has provided new insight into the biology of myeloma, finding that MGUS...
On location

IMWG Revises International Staging System for Multiple Myeloma

At this year’s International Myeloma Working Group (IMWG) Summit, this large team of myeloma experts released a revised International Staging System (R-ISS) for newly...
On location

Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients

Elotuzumab, a novel anti-SLAMF7 monoclonal antibody, extended multiple myeloma (MM) patients’ duration of remission by about five months, on average, compared with standard treatment...

Safety Profile of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients

For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, as with other monoclonal antibody therapies, management of infusion-related reactions (IRRs)...

Recently Approved Agents

In 2015, the U.S. Food and Drug Administration approved two agents for the treatment of patients with multiple myeloma (MM): the HDAC inhibitor panobinostat...
On location

Safety and Tolerability of MOR202 in Relapsed/Refractory Myeloma Patients

A recent phase I/IIa study evaluated the safety and efficacy of MOR202, a human monoclonal anti-CD38 antibody, in adult patients with relapsed/refractory multiple myeloma...

Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients

Results from an analysis presented at the 2015 ASH Meeting on Hematologic Malignancies confirm that T-cell exhaustion and senescence (occurring when T cells are...

Clinical Trial Updates

A look at the ongoing clinical trials in multiple myeloma. PHASE III TRIALS A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo...

Fusion Protein Therapies for Hemophilia A and B

Patients with hemophilia A and B may benefit from the less-frequent dosing regimens of two recently FDA-approved fusion protein therapies: recombinant coagulation factor VIII...

Optimizing Treatment of Bleeding Episodes in Acquired Hemophilia A

Two studies reported at the 2014 ASH Annual Meeting described how to best optimize OBI-1 (antihemophilic factor , porcine sequence), which was recently approved...
Advertisement

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title